Core Insights - The company will present early preclinical data on its next-generation Emperor Total Artificial Heart at the ACC.26 conference in New Orleans from March 28 to March 30, 2026 [1][3] Company Overview - Picard Medical, Inc. is the parent company of SynCardia Systems LLC, which developed the first total artificial heart approved by both the U.S. FDA and Health Canada [1][7] - SynCardia's Total Artificial Heart is the only commercially available artificial heart technology in the U.S. and Canada, with over 2,100 implants performed across 27 countries [7] Product Development - The Emperor Total Artificial Heart is designed as a fully implantable electromechanical system that aims to preserve physiological autoregulation and hemodynamic performance [3][6] - The new system is intended to provide long-term support while improving mobility and quality of life for patients with advanced heart failure [6] Conference Participation - SynCardia will exhibit at booth 2554 during the ACC.26 conference, providing opportunities for attendees to meet with engineering and clinical teams [4][5] - The conference will serve as a platform for discussing the design, development progress, and future clinical direction of the Emperor Total Artificial Heart [5]

Core Insights - Picard Medical, Inc. will participate in the inaugural "Hands-On Training Day" at the THT 2026 conference to enhance education on the SynCardia Total Artificial Heart for advanced heart failure patients [1][2] Company Overview - Picard Medical is the parent company of SynCardia Systems, which produces the only commercially available total artificial heart approved by the U.S. FDA and Health Canada [6] - The SynCardia Total Artificial Heart has been implanted over 2,100 times across 27 countries, making it the most widely used artificial heart globally [6] Training Program Details - The training program will feature interactive, case-based learning aimed at improving multidisciplinary collaboration and patient outcomes in advanced heart failure [2][4] - Clinicians will engage with the technology through hands-on training, focusing on real-world clinical scenarios [3][4] - Senior Clinical Specialists will lead the training, providing direct interaction with the Companion 2 Driver, Freedom Portable Driver, and the SynCardia Total Artificial Heart [3] Conference Information - The THT 2026 conference focuses on advancing heart failure innovation through emerging devices and therapies, bringing together clinicians, researchers, and industry partners [5] - The program includes scientific sessions, case discussions, and hands-on training to foster collaboration and improve patient outcomes [5]

Core Viewpoint - Picard Medical, Inc. is hosting an exclusive training program for the SynCardia Total Artificial Heart, aimed at enhancing surgical education and collaboration among leading cardiac centers in the U.S. [1][5] Group 1: Training Initiative - The "SynCardia Total Artificial Heart Training Village" will take place at Houston Methodist Hospital, featuring advanced programs on implantation techniques and clinical best practices [2][5] - The program will be led by Dr. Andre Simon, an expert in mechanical circulatory support, combining classroom instruction with hands-on surgical training [3][4] - The initiative aims to improve patient care for those with advanced heart failure through peer-to-peer surgical education and collaborative discussions [4][5] Group 2: Strategic Goals - The training initiative is part of Picard Medical's broader strategy to develop centers of excellence across the U.S. to expand access to total artificial heart therapy [5][8] - The Houston region is identified as a significant market for advanced heart failure, and the program aims to enhance collaboration among high-volume transplant and mechanical circulatory support programs [5][8] - The company plans additional training initiatives in key markets to increase implant volumes and broaden access to the SynCardia Total Artificial Heart [5][8] Group 3: Company Background - Picard Medical, Inc. is the parent company of SynCardia Systems, which offers the only commercially available total artificial heart technology for end-stage heart failure [8][9] - The SynCardia Total Artificial Heart has been implanted over 2,100 times across 27 countries, making it the most widely used artificial heart globally [9]